subject area of
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer Academic Article
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy Academic Article
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2 Academic Article
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 Academic Article
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study Academic Article
- Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators Academic Article
- Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent Academic Article
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Academic Article
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma Academic Article
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer Academic Article
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Academic Article
- Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease Academic Article
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2−advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy Academic Article
- Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial Academic Article
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 Academic Article
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade Academic Article
- Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition Academic Article
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer Academic Article
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 Conference Paper
- Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2 Academic Article
- Surgical biology for the clinician: vascular effects of immunosuppression. Academic Article
- Targeted therapy for metastatic renal cell carcinoma Academic Article